DRUG REPOSITIONING FOR COLON CANCER TREATMENT: EXPLORING THE PUTATIVE USE OF METFORMIN AND PROPRANOLOL

MARIA JOSE RICO; MARTINEZ MARIGNAC VERONICA L; LUCIANO ANSELMINO; BAGLIONI MV; G SCHAROVSKY; CLAUDIO FERNANDEZ; MAURICIO MENACHO MARQUEZ

BUENOS AIRES

Congreso; REUNION CONJUNTA DE SOCIEDADES EN BIOCIENCIAS; 2017

SAIC, SAFE, SAIB, SAP, SAH SAA,

Drug repositioning or repurposing in oncology refers to the use of drugs originally formulated for other indications that showed antitumorpotential. In this work we made a screening of repurposingdrugs that included metformin (M; diabetes treatment), propranolol(P; indicated to treat hypertension), chloroquine (malaria treatmentor prevention), DHEA (sexual hormones precursor), orlistat (obesitytreatment), atorvastatin (cholesterol treatment) and dichloroacetate(a pyruvate dehydrogenase kinase inhibitor). The antitumor potentialof these drugs was evaluated in vitro with HCT116 human coloncancer cells through standard viability assays, either individuallyor in a combined manner. All the tested drugs had the potential toinhibit significantly HCT116 cells proliferation in a dose-dependentmanner. From the combinations tested, M+P resulted attractive as itshowed a strong growth inhibition even combining low doses of bothdrugs (P